Israel has not only emerged as a pioneering force in developing innovative medtech use cases, but the Startup Nation is also showing strength in scaling its products for the world stage. As more opportunities in the West and East emerge, it’s clear that Israeli medical technology has a bright future. 

Boosted by robust government infrastructure, Israel’s medtech sector is a key market player in digital health, medical devices, biotechnology, and pharmaceutical therapeutics. The nation’s commitment to delivering leading healthcare has attracted plenty of interest from the Americas, Europe, and East Asia. 

The resilience of the sector has been tested repeatedly in recent years, and a strong flurry of landmark M&A activity shows that Israel’s medtech sector remains as strong as ever. 

One of the most notable signs of Israel’s robust market stemmed from Johnson & Johnson’s $1.7 billion acquisition of Caesarea-headquartered heart failure technology company V-Wave in 2024. 

However, other major instances of M&A activity, such as Boston Scientific’s acquisition of SoniVie last year and the 2024 purchase of transcatheter mitral valve replacement company Innovalve Bio Medical by Edwards Lifesciences, demonstrate Israel’s strength on the world stage when it comes to advanced healthcare. 

Such is the power of Israel’s medtech innovation pipelines that Joe Mullings, CEO of the Mullings Group of Companies, suggested that the nation isn’t merely punching above its weight when it comes to medical technologies but is changing the face of medical devices globally.

Israel’s MedTech Pedigree

Investments in Israeli medtech have been growing exponentially in recent years. In 2024, we saw life-science investment in Israel reach $2.7 billion, representing a 25% increase on the year prior. Likewise, exports of Israeli-made technologies climbed to $3.4 billion, representing its highest level for five years. 

These figures are driven by the collective ambitions of local businesses to solve key challenges, supporting safer clinical practices and providing more accessible care. 

More recently, Israel’s medtech landscape has expanded to incorporate AI-enhanced imaging, wearable monitoring, and minimally invasive procedures, paving the way for human-centric healthcare that’s not only cost-effective but capable of improving outcomes for patients. 

2024 saw medtech funding rounds reach three figures, totaling $4.6 billion, and there are plenty of signs that interest in Israeli innovators is still as high as ever in 2026. 

February 2026 saw Medtronic underline its bold commitment to step up acquisitions this year by paying $585 million to buy its privately held partner, the Israel-based CathWorks, which is a key player in combating coronary artery disease. 

The move represents a timely statement of intent that shows Israeli medtech firms are still capable of generating more lucrative exits than ever before. 

It’s also a testament to the sector’s patient-oriented approach that more global healthcare giants keep coming back for Israel’s leading innovators. 

Building on the World Stage

Israel’s strength as a global medtech leader is helping to develop a brand new form of innovation pipeline whereby international businesses are opening new offices domestically to smooth the path to new markets. 

December 2025 saw US firm The Mullings Group open an office in Israel in a bid to support domestic medtech companies in expanding into the United States. 

The company’s aims involve the provision of help in achieving FDA clearance, commercialization, and scaling into US markets without forcing company founders to relocate. 

The Florida-based firm, focused on talent access, media, and advisory services, would be seeking to accelerate the growth of the global medtech sector by allowing Israeli innovators to scale faster internationally, bringing widespread access to new technologies and products. 

To the east, Israeli firms are also well-positioned to benefit from a renewed emphasis by the Chinese government towards healthcare innovation. 

As part of the Healthy China 2030 plan, the scaling of Israeli medtech firms could see more startups enter Chinese markets to develop advanced medical technologies in underserved areas. 

China is already a trailblazer in fostering the development of artificial intelligence, and the emergence of enhanced government support throughout the industry illustrates the potential that the market holds for Israeli firms. 

Government support for listed medtech companies in China far outweighs OECD averages, representing around 4.5% of revenue as opposed to 0.7%. This means that the newfound international popularity of Israeli innovators has come at a critical time for securing the support needed to scale throughout 2026 and beyond. 

What’s Next for Medtech

Medtech is one of the world’s most exciting emerging sectors, capable of incorporating AI and big data into actionable support for patients around the world, boosting longevity and easing suffering at scale. 

Israel’s human-centric approach to medtech has not only helped the Startup Nation to emerge as one of the world’s most innovative industry players; but it’s also drawn international attention for cutting-edge use cases, resulting in an uptick in acquisitions and market expansions. 

Looking ahead, Israel is in a uniquely strong position to grow its medtech capabilities as more leading economies in the east and west invest heavily in healthcare, supporting more scale-up initiatives and more foreign interest in an industry that promises to bring sweeping benefits for all.

© The Times of Israel (Blogs)